Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $52.77 Consensus Target Price from Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received an average rating of “Moderate Buy” from the fourteen research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $54.6154.

Several equities analysts recently weighed in on the stock. UBS Group lifted their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Wells Fargo & Company increased their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a report on Wednesday. Guggenheim raised their price objective on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Canaccord Genuity Group reduced their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 15th.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $38.06 on Friday. Celldex Therapeutics has a one year low of $19.72 and a one year high of $40.30. The company’s 50 day moving average price is $34.30 and its 200 day moving average price is $31.03. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -8.93 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.80 million. Sell-side analysts forecast that Celldex Therapeutics will post -4.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. raised its stake in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the third quarter worth $63,000. Kestra Advisory Services LLC acquired a new position in shares of Celldex Therapeutics during the fourth quarter worth $98,000. Finally, Advisory Services Network LLC acquired a new position in shares of Celldex Therapeutics during the third quarter worth $139,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.